Epigenetic regulation refers to regulating gene expression and structure without altering genome sequence, which regulates the compaction of chromatins and further influences gene expression to affect human health and disease. Over the past few years, the epigenetic regulation mechanisms in cardiovascular disease have attracted widespread attention. Cardiac remodeling, a pathological process of many myocardial diseases, can eventually lead to heart failure. To date, it is shown that multiple epigenetic mechanisms are involved in the regulation of cardiac remodeling. For example, JMJD2A can accentuate TAC surgery-induced cardiac hypertrophy by decreasing the level of H3K9me3 and further increasing the expression of hypertrophy genes in cardiomyocytes. Moreover, recent studies have shown that epigenetics is associated with various vascular diseases. For example, EZH2 was found to inhibit the autophagy of VSMCs and further affect aortic dissection. Hence, studies targeting at epigenetic mechanisms may unveil a new direction for the treatment of cardiac remodelingand vascular diseases.
In this Research Topic, we would like to create a forum for current advances on epigenetic regulation in cardiovascular disease (CVD), especially cardiac remodeling and vascular diseases. As we know, epigenetic mechanisms involve in almost all pathological and physiological processes of the body, such as organ development, cell proliferation and differentiation, aging, cell death. Although there have been researches on the role of epigenetic regulation in cardiovascular disease, a comprehensive understand remains undisclosed. More importantly, development of epigenetic regulation related drugs, for clinical use in safety and efficacy, is of crucial and urgent needs.
Suggested paper themes include:
1) Epigenetic mechanisms: post-translational histone modifications, DNA methylation and noncoding RNAs.
2) DNA methylation in cardiac remodeling and vascular diseases.
3) Post-translational histone modifications in cardiac remodeling and vascular diseases: histone acetylation in cardiac remodeling and vascular diseases, HDACs inhibitors in cardiac remodeling and vascular diseases, histone phosphorylation in cardiac remodeling and vascular diseases, histone ubiquitination in cardiac remodeling and vascular diseases, histone methylation in cardiac remodeling and vascular diseases, the inhibitors of methyltransferases in cardiac remodeling and vascular diseases.
4) RNA-based epigenetics in cardiac remodeling and vascular diseases: noncoding RNAs in cardiac remodeling and vascular diseases.
Epigenetic regulation refers to regulating gene expression and structure without altering genome sequence, which regulates the compaction of chromatins and further influences gene expression to affect human health and disease. Over the past few years, the epigenetic regulation mechanisms in cardiovascular disease have attracted widespread attention. Cardiac remodeling, a pathological process of many myocardial diseases, can eventually lead to heart failure. To date, it is shown that multiple epigenetic mechanisms are involved in the regulation of cardiac remodeling. For example, JMJD2A can accentuate TAC surgery-induced cardiac hypertrophy by decreasing the level of H3K9me3 and further increasing the expression of hypertrophy genes in cardiomyocytes. Moreover, recent studies have shown that epigenetics is associated with various vascular diseases. For example, EZH2 was found to inhibit the autophagy of VSMCs and further affect aortic dissection. Hence, studies targeting at epigenetic mechanisms may unveil a new direction for the treatment of cardiac remodelingand vascular diseases.
In this Research Topic, we would like to create a forum for current advances on epigenetic regulation in cardiovascular disease (CVD), especially cardiac remodeling and vascular diseases. As we know, epigenetic mechanisms involve in almost all pathological and physiological processes of the body, such as organ development, cell proliferation and differentiation, aging, cell death. Although there have been researches on the role of epigenetic regulation in cardiovascular disease, a comprehensive understand remains undisclosed. More importantly, development of epigenetic regulation related drugs, for clinical use in safety and efficacy, is of crucial and urgent needs.
Suggested paper themes include:
1) Epigenetic mechanisms: post-translational histone modifications, DNA methylation and noncoding RNAs.
2) DNA methylation in cardiac remodeling and vascular diseases.
3) Post-translational histone modifications in cardiac remodeling and vascular diseases: histone acetylation in cardiac remodeling and vascular diseases, HDACs inhibitors in cardiac remodeling and vascular diseases, histone phosphorylation in cardiac remodeling and vascular diseases, histone ubiquitination in cardiac remodeling and vascular diseases, histone methylation in cardiac remodeling and vascular diseases, the inhibitors of methyltransferases in cardiac remodeling and vascular diseases.
4) RNA-based epigenetics in cardiac remodeling and vascular diseases: noncoding RNAs in cardiac remodeling and vascular diseases.
